GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TGTX · Mar 31, 2025

TG THERAPEUTICS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-015804General Corporate
Capex intensity33thOwn-history percentile · N=9
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.02% · OPTIONAL · VALID

Operating cash generation60thOwn-history percentile · N=15
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-23.76% · OPTIONAL · VALID

Revenue growth45thOwn-history percentile · N=11
Evidence method

Yoy · gp.fundamentals.revenue

90.40% · CORE · VALID

Inventory pressure75thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

130.53% · OPTIONAL · VALID

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

87.14% · CORE · NOT_ENOUGH_HISTORY

Operating margin67thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.operating_margin

7.13% · CORE · VALID

R&D intensity33thOwn-history percentile · N=15
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

38.36% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

12.39% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible
Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20235/7 normalizedLevel 3Sep 30, 20235/8 normalizedLevel 3Dec 31, 20235/9 normalizedLevel 3Mar 31, 20244/7 normalizedLevel 3Jun 30, 20245/7 normalizedLevel 3Sep 30, 20245/7 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.01%
Current
0.02%
Delta
0.01%
Cash Generation Decreased
Previous
-12.31%
Current
-23.76%
Delta
-11.44%
Growth Increased
Previous
40.80%
Current
90.40%
Delta
49.60%
Inventory Pressure Increased
Previous
33.57%
Current
130.53%
Delta
96.96%
Margin Decreased
Previous
88.30%
Current
87.14%
Delta
-1.16%
Profitability Decreased
Previous
12.74%
Current
7.13%
Delta
-5.61%
R And D Intensity Increased
Previous
28.66%
Current
38.36%
Delta
9.70%
Sbc Intensity Decreased
Previous
12.93%
Current
12.39%
Delta
-0.54%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · TGTX Fundamental State →Has State · TG THERAPEUTICS, INC. →Transitioned To · TGTX Fundamental State →Transitioned To · TGTX CAPEX_INTENSITY_INCREASED →Transitioned To · TGTX CASH_GENERATION_DECREASED →Transitioned To · TGTX GROWTH_INCREASED →Transitioned To · TGTX INVENTORY_PRESSURE_INCREASED →Transitioned To · TGTX MARGIN_DECREASED →Transitioned To · TGTX PROFITABILITY_DECREASED →Transitioned To · TGTX R_AND_D_INTENSITY_INCREASED →Transitioned To · TGTX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.